DOCSLIB.ORG

Liste Positive Des Médicaments Valable Au 1Er Mai 2021 Cette Liste

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Liste Positive Des Médicaments Valable Au 1Er Mai 2021 Cette Liste Liste positive des médicaments valable au 1er mai 2021 Cette liste se base sur des données qui sont de la compétence de la Division de la Pharmacie et des Médicaments et du Ministère de la sécurité sociale. Numéro Dénomination abrégée Prise en charge conditionnelle Prix public Taux national Type-Détail A01AA01 sodium fluoride 0131307 ZYMAFLUOR CPR. 0,25 MG 1*250 CPR. 0 - 0 4,62 80 0131324 ZYMAFLUOR CPR. 1 MG 1*250 CPR. 0 - 0 6,95 80 A01AB03 chlorhexidine 0207727 CORSODYL SOL. BAIN BOUCHE 10 MG / 5 ML 1*1 SOL. 200 ML 0 - 0 5,79 40 A01AB09 miconazole 0027634 DAKTARIN GEL ORAL 20 MG / 1 G 1*1 GEL 40 G 0 - 0 7,64 80 A01AB12 hexetidine 0053603 HEXTRIL SOL. BAIN BOUCHE 5 MG / 5 ML 1*1 FLACON 200 ML 0 - 0 5,67 40 A02AB10 combinations 0655811 MAALOX ANTACID CITRON SP.BUV. 230 MG / 4,3 ML + 400 MG 0 - 0 9,29 40 / 4,3 ML 1*20 SACH. 0655838 MAALOX ANTACID SANS SUCRE CITRON CPR. CROQUER 200 0 - 0 5,92 40 MG + 400 MG 1*40 CPR.SS BLIST. A02AD01 ordinary salt combinations 0643421 MAALOX ANTACID- 200MG/400MG CPR. CROQUER 1*100 0 - 0 10,27 40 CPR.SS BLIST. 0643434 MAALOX ANTACID- 200MG/400MG CPR. CROQUER 1*40 0 - 0 5,15 40 CPR.SS BLIST. 0790765 MAALOX ANTACID- 230MG/400MG SP.BUV. 230 MG / 10 ML + 0 - 0 8,92 40 400 MG / 10 ML 1*1 FLACON 250 ML 0643448 MAALOX ANTACID- 230MG/400MG SP.BUV. 230 MG / 10 ML + 0 - 0 8,48 40 400 MG / 10 ML 1*1 FLACON 355 ML A02AD02 magaldrate 0255299 GASTRICALM CPR. CROQUER 1*50 CPR.SS BLIST. 0 - 0 9,62 40 0100197 RIOPAN SP.BUV. 800 MG / 10 ML 1*20 SACHETS 10 ML 0 - 0 8,70 40 0511791 RIOPAN SP.BUV. 800 MG / 10 ML 1*50 SACHETS 10 ML 0 - 0 17,39 40 A02AD04 hydrotalcite 0253862 TALIDAT CPR. 500 MG 1*100 CPR.A MACHER 0 - 0 16,02 40 0253845 TALIDAT CPR. 500 MG 1*20 CPR.A MACHER 0 - 0 4,50 40 0253859 TALIDAT CPR. 500 MG 1*50 CPR.A MACHER 0 - 0 9,51 40 A02AX Antacids, other combinations 0156595 SYNGEL SP.BUCC. 1*1 FLACON 300 ML 0 - 0 14,09 40 A02BA02 ranitidine 0218555 RANITIC-150 CPR.ENR. 150 MG 1*100 CPR.SS BLIST. 0 - 0 17,18 80 0218538 RANITIC-150 CPR.ENR. 150 MG 1*20 CPR.SS BLIST. 0 - 0 10,59 80 0218541 RANITIC-150 CPR.ENR. 150 MG 1*50 CPR.SS BLIST. 0 - 0 13,31 80 0218524 RANITIC-300 CPR.ENR. 300 MG 1*100 CPR.SS BLIST. 0 - 0 25,59 80 0218507 RANITIC-300 CPR.ENR. 300 MG 1*20 CPR.SS BLIST. 0 - 0 12,64 80 0218511 RANITIC-300 CPR.ENR. 300 MG 1*50 CPR.SS BLIST. 0 - 0 17,50 80 0543926 RANITIDINE EG-150 CPR.EFF. 150 MG 1*112 CPR.(TUBE) 0 - 0 12,06 80 0446628 RANITIDINE EG-150 CPR.ENR. 150 MG 1*112 CPR.SS BLIST. 0 - 0 9,96 80 0286314 RANITIDINE EG-150 CPR.ENR. 150 MG 1*56 CPR.SS BLIST.U.D. 0 - 0 8,71 80 0544047 RANITIDINE EG-300 CPR.EFF. 300 MG 1*28 CPR.(TUBE) 0 - 0 7,97 80 0544064 RANITIDINE EG-300 CPR.EFF. 300 MG 1*56 CPR.(TUBE) 0 - 0 17,48 80 0286328 RANITIDINE EG-300 CPR.ENR. 300 MG 1*28 CPR.SS BLIST.U.D. 0 - 0 7,53 80 0446631 RANITIDINE EG-300 CPR.ENR. 300 MG 1*56 CPR.SS BLIST. 0 - 0 8,14 80 A02BB01 misoprostol 0027262 CYTOTEC-200 CPR. 0,2 MG 1*112 CPR. 0 - 0 36,30 80 A02BC01 omeprazole 0279077 LOSEC-MUPS 10 MG CPR.GASTRO-RES. 10 MG 1*28 CPR.SS 6 - AA 16,40 80 BLIST. 0279081 LOSEC-MUPS 10 MG CPR.GASTRO-RES. 10 MG 1*56 CPR.SS 6 - AA 12,85 80 BLIST. 0279113 LOSEC-MUPS 20 MG CPR.GASTRO-RES. 20 MG 1*28 CPR.SS 6 - AA 24,00 80 BLIST. 0409543 LOSEC-MUPS 20 MG CPR.GASTRO-RES. 20 MG 1*56 CPR.SS 6 - AA 18,52 80 BLIST. 0279144 LOSEC-MUPS 40 MG CPR.GASTRO-RES. 40 MG 1*28 CPR.SS 6 - AA 44,09 80 BLIST. 0615085 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 10 MG 6 - AA 17,49 80 1*100 GELUL. 0615054 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 10 MG 6 - AA 10,39 80 Page 1 of 97 Numéro Dénomination abrégée Prise en charge conditionnelle Prix public Taux national Type-Détail 1*15 GELUL. 0615068 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 10 MG 6 - AA 11,47 80 1*30 GELUL. 0615071 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 10 MG 6 - AA 13,06 80 1*50 GELUL. 0615149 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 20 MG 6 - AA 21,19 80 1*100 GELUL. 0615104 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 20 MG 6 - AA 10,79 80 1*15 GELUL. 0615118 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 20 MG 6 - AA 12,37 80 1*30 GELUL. 0615121 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 20 MG 6 - AA 14,71 80 1*50 GELUL. 0615135 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 20 MG 6 - AA 15,94 80 1*60 GELUL. 0615216 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 40 MG 6 - AA 26,60 80 1*100 GELUL. 0615166 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 40 MG 6 - AA 11,37 80 1*15 GELUL. 0615183 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 40 MG 6 - AA 13,70 80 1*30 GELUL. 0615197 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 40 MG 6 - AA 17,13 80 1*50 GELUL. 0615202 OMEPRAZOL-RATIOPHARM NT GELUL.GASTRO-RES. 40 MG 6 - AA 18,93 80 1*60 GELUL. 0714228 OMEPRAZOLE EG GELUL.GASTRO-RES. 10 MG 1*100 6 - AA 16,80 80 GÉLULES (FLACON) 0714262 OMEPRAZOLE EG GELUL.GASTRO-RES. 10 MG 1*28 GÉLULES 6 - AA 8,16 80 SS BLIST. 0714195 OMEPRAZOLE EG GELUL.GASTRO-RES. 10 MG 1*56 GÉLULES 6 - AA 13,02 80 (FLACON) 0714651 OMEPRAZOLE EG GELUL.GASTRO-RES. 20 MG 1*100 6 - AA 23,08 80 GÉLULES (FLACON) 0714407 OMEPRAZOLE EG GELUL.GASTRO-RES. 20 MG 1*14 GÉLULES 6 - AA 8,03 80 SS BLIST. 0714424 OMEPRAZOLE EG GELUL.GASTRO-RES. 20 MG 1*28 GÉLULES 6 - AA 12,12 80 SS BLIST. 0714621 OMEPRAZOLE EG GELUL.GASTRO-RES. 20 MG 1*56 GÉLULES 6 - AA 18,52 80 (FLACON) 0714925 OMEPRAZOLE EG GELUL.GASTRO-RES. 40 MG 1*100 6 - AA 43,19 80 GÉLULES (FLACON) 0714696 OMEPRAZOLE EG GELUL.GASTRO-RES. 40 MG 1*28 GÉLULES 6 - AA 18,67 80 SS BLIST. 0714892 OMEPRAZOLE EG GELUL.GASTRO-RES. 40 MG 1*56 GÉLULES 6 - AA 31,89 80 (FLACON) 0370919 SEDACID CPR.GASTRO-RES. 10 MG 1*14 CPR. 6 - AA 6,80 80 0370922 SEDACID CPR.GASTRO-RES. 10 MG 1*28 CPR. 6 - AA 7,94 80 0370936 SEDACID CPR.GASTRO-RES. 10 MG 1*56 CPR. 6 - AA 12,31 80 0482073 SEDACID CPR.GASTRO-RES. 20 MG 1*100 CPR. 6 - AA 21,84 80 0370953 SEDACID CPR.GASTRO-RES. 20 MG 1*14 CPR. 6 - AA 7,94 80 0370967 SEDACID CPR.GASTRO-RES. 20 MG 1*28 CPR. 6 - AA 11,98 80 0370971 SEDACID CPR.GASTRO-RES. 20 MG 1*56 CPR. 6 - AA 17,73 80 A02BC02 pantoprazole 0643417 IPRAALOX 20MG CPR.GASTRO-RES. 20 MG 1*14 CPR.SS 6 - AA 9,53 80 BLIST. 0489804 PANTOMED-20 CPR.GASTRO-RES. 20 MG 1*100 CPR.SS 6 - AA 15,16 80 BLIST. 0489723 PANTOMED-20 CPR.GASTRO-RES. 20 MG 1*28 CPR.SS BLIST. 6 - AA 7,70 80 0489754 PANTOMED-20 CPR.GASTRO-RES. 20 MG 1*56 CPR.SS BLIST. 6 - AA 10,94 80 0490061 PANTOMED-40 CPR.GASTRO-RES. 40 MG 1*100 CPR.SS 6 - AA 26,22 80 BLIST. 0489978 PANTOMED-40 CPR.GASTRO-RES. 40 MG 1*28 CPR.SS BLIST. 6 - AA 11,70 80 0490013 PANTOMED-40 CPR.GASTRO-RES. 40 MG 1*56 CPR.SS BLIST. 6 - AA 18,57 80 0670168 PANTOPRAZOL SANDOZ CPR.GASTRO-RES. 20 MG 1*28 CPR. 6 - AA 7,68 80 (FL.) 0670171 PANTOPRAZOL SANDOZ CPR.GASTRO-RES. 20 MG 1*56 CPR. 6 - AA 10,78 80 (FL.) 0670185 PANTOPRAZOL SANDOZ CPR.GASTRO-RES. 20 MG 1*98 CPR. 6 - AA 14,96 80 (FL.) 0670235 PANTOPRAZOL SANDOZ CPR.GASTRO-RES. 40 MG 1*28 CPR. 6 - AA 11,39 80 (FL.) 0670249 PANTOPRAZOL SANDOZ CPR.GASTRO-RES. 40 MG 1*56 CPR. 6 - AA 18,57 80 (FL.) 0670252 PANTOPRAZOL SANDOZ CPR.GASTRO-RES. 40 MG 1*98 CPR. 6 - AA 25,28 80 (FL.) 0494043 PANTOPRAZOL-RATIOPHARM CPR.GASTRO-RES. 20 MG 6 - AA 19,48 80 1*100 CPR.SS BLIST. Page 2 of 97 Numéro Dénomination abrégée Prise en charge conditionnelle Prix public Taux national Type-Détail 0494009 PANTOPRAZOL-RATIOPHARM CPR.GASTRO-RES. 20 MG 1*30 6 - AA 11,96 80 CPR.SS BLIST. 0494026 PANTOPRAZOL-RATIOPHARM CPR.GASTRO-RES. 20 MG 1*60 6 - AA 15,01 80 CPR.SS BLIST. 0496602 PANTOPRAZOL-RATIOPHARM CPR.GASTRO-RES. 40 MG 6 - AA 24,76 80 1*100 CPR.SS BLIST. 0493788 PANTOPRAZOL-RATIOPHARM CPR.GASTRO-RES.
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Age-Related Decrease in Resilience Against Acute Redox Cycling Agents: Critical Role of Declining GSH-Dependent Detoxification Capacity
    AN ABSTRACT OF THE DISSERTATION OF Nicholas Oliver Thomas for the degree of Doctor of Philosophy in Biochemistry and Biophysics presented on June 16, 2017 Title: Age-related Decrease in Resilience Against Acute Redox Cycling Agents: Critical Role of Declining GSH-dependent Detoxification Capacity Abstract approved: Tory M. Hagen Over the past century, life expectancy in the United States has dramatically increased leading to an increasingly aging population with people reaching, and spending more years in ‘old age’. While this unprecedented shift in population demographics represents great strides for humanity, it is not without cost. One consequence of longer life is the increased accrual of age-associated diseases and chronic pathophysiological conditions. This is evident in the fact that over 80% of Americans over the age of 65 have at least one chronic medical condition [275]. Thus, lifespan has outpaced ‘healthspan’, or the time of one’s life spent free from disease and disuse syndromes. The work in this dissertation is defined by the investigation of “health assurance” biochemical pathways, the failure of which lead to heightened risk for age-related diseases. In particular, I have focused on why resiliency to oxidative stresses decline significantly with age. This focus has led to a research project that ultimately pinpoints a loss in glutathione-dependent defenses as an underlying aging factor, which could enhance risk for a variety of age-related diseases. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a major transcriptional regulator of numerous anti-oxidant, anti-inflammatory, and metabolic genes. We observed that, paradoxically, Nrf2 protein levels decline in the livers of aged rats despite the inflammatory environment evident in that organ.
    [Show full text]
  • Age-Related Loss of Nrf2, a Novel Mechanism for the Potential
    AN ABSTRACT OF THE DISSERTATION OF Eric Jonathan Smith for the degree of Doctor of Philosophy in Biochemistry and Biophysics presented on June 11th, 2014 Title: Age-related Loss of Nrf2, a Novel Mechanism for the Potential Attenuation of Xenobiotic Detoxification Capacity Abstract approved: Tory M. Hagen Nuclear Factor, Erythroid Derived 2, Like 2 (NFE2L2 or Nrf2) is the primary transcription factor in cellular defense against oxidative and xenobiotic stresses in higher eukaryotes. This basic leucine zipper transcription factor regulates over 200 antioxidant, detoxification, and lipid metabolizing genes by binding to the Antioxidant Response Element (ARE; a cis-acting element) as a transcription enhancer. Our group, and others, have identified that the nuclear steady state levels of this highly inducible transcription factor declines with age which coincides with decreased expression of many ARE regulated genes. To elucidate the mechanism(s) involved in lowered Nrf2 levels we used hepatocytes isolated from young and old rats as a relevant cellular model that maintains the aging phenotype with respect to Nrf2 levels. Our results show that steady state Nrf2 levels decline by ~40% with age (N=4, p<0.05), which led us to investigate the multifaceted regulation of Nrf2 homeostasis. Specifically, analysis of Nrf2 mRNA levels, and the rate of Nrf2 protein turnover and translation were investigated. Surprisingly, Keap1-mediated degradation of Nrf2, its primary negative regulator, did not account for the age-related Nrf2 decline, nor did mRNA levels change with age. Rather, Nrf2 protein synthesis declines 5.3-fold with age (N=3, p<0.05). Furthermore, we identify that rno-miR-146a, a key inflammation regulating miRNA, both inhibits Nrf2 translation and increases significantly with age.
    [Show full text]
  • The Development of Novel Cysteine Cross-Linkers and Their Application Towards Neurodegenerative Disorders
    The Development of Novel Cysteine Cross-linkers and Their Application Towards Neurodegenerative Disorders by Daniel Patrick Donnelly B.A. in English Literature, New York University B.S. in Chemistry, Salem State University A dissertation submitted to The Faculty of the College of Science of Northeastern University in partial fulfillment of the requirements for the degree of Doctor of Philosophy April 9th, 2019 Dissertation directed by Jeffrey N. Agar Associate Professor of Chemistry and Chemical Biology & Pharmaceutical Sciences 1 Dedication To my mother, Loretta Yannaco, my father, Robert Jude Donnelly (Jan 26, 1955-Dec 3, 2015), my sister and brother Claire Donnelly and Nicholas Rieber, and my soon-to-be wife, Rebecca Towers for your constant support over the years. I truly would not be where I am today without you. Thank you. 2 Acknowledgements I must first acknowledge my advisor, my mentor, my boss, and my friend, Jeffrey N. Agar, for his constant support and guidance throughout my Ph.D. The training, skillset, and knowledge I have gained under his mentorship is immeasurable. Jeff taught me that good research is thorough research, that publishing in high-impact journals is tedious but worth it, and that scientific problems can be approached from a number of angles. I am a better scientist as a result of his mentorship. I would like to thank the current and former Agar Lab members: Dr. Catherine M. Rawlins, for being an exceptional colleague, collaborator, and, most importantly, friend; Dr. Jeniffer V. Quijada, for being a mentor, teacher, and friend throughout my first years at Northeastern University; Nicholas D.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,771,755 B2 Gojon-Romanillos Et Al
    US008.771755B2 (12) United States Patent (10) Patent No.: US 8,771,755 B2 Gojon-Romanillos et al. (45) Date of Patent: Jul. 8, 2014 (54) PREPARATION AND COMPOSITIONS OF International Search Report and Written Opinion for International HIGHLY BOAVAILABLE ZEROVALENT Application No. PCT/MX12/00086, mailed Mar. 27, 2013. Abdolrasulnia et al., “Transfer of persulfide sulfur from thiocystine to SULFUR AND USES THEREOF rhodanese.” Biochim. Biophys. Acta. 567:135-143, 1979 (Abstract only). (75) Inventors: Gabriel Gojon-Romanillos, San Pedro Abe et al., “The Possible Role of Hydrogen Sulfide as an Endogenous Garza García (MX); Gabriel Neuromodulator.” The Journal of Neuroscience 16:1066-1071, 1996. Gojon-Zorrilla, San Pedro Garza García Agarwal et al., “Clinical Relevance of Oxidative Stress in Male Factor Infertility: An Update.” American Journal of Reproductive (MX) Immunology 59:2-11, 2008. Agarwal et al., “Oxidative stress and antioxidants for idiopathic (73) Assignee: Nuevas Alternativas Naturales, S.A.P.I. oligoasthenoteratospermia: Is it justified?” Indian J. Urol. 27:74-85, de C.V., Monterrey (MX) 2011 (Abstract only). Agarwal et al., “Oxidative stress and antioxidants in male infertility: (*) Notice: Subject to any disclaimer, the term of this a difficult balance.” Iranian Journal of Reproductive Medicine3: 1-8, patent is extended or adjusted under 35 2005. U.S.C. 154(b) by 0 days. Agarwal et al., “Role of Oxidative Stress in the Pathophysiological Mechanism of Erectile Dysfunction.” Journal of Andrology 27:335 347, 2006. (21) Appl. No.: 13/614,820 Aggarwal, "Nuclear factor-KB:The enemy within.” Cancer Cell 6:203-208, 2004. (22) Filed: Sep.
    [Show full text]
  • Uncovering Active Modulators of Native Macroautophagy Through
    bioRxiv preprint doi: https://doi.org/10.1101/756973; this version posted September 4, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 1 Title: Uncovering active modulators of native macroautophagy through novel 2 high-content screens 3 4 Author list: Safren N1, Tank EM1, Santoro N2, and Barmada SJ1* 5 6 Affiliations: 1University of Michigan, Department of Neurology, Ann Arbor MI, 2University 7 of Michigan, Center for Chemical Genomics, Life Sciences Institute 8 9 *Correspondence addressed to: [email protected] 10 11 12 Abstract 13 Autophagy is an evolutionarily conserved pathway mediating the breakdown of cellular 14 proteins and organelles. Emphasizing its pivotal nature, autophagy dysfunction 15 contributes to many diseases; nevertheless, development of effective autophagy 16 modulating drugs is hampered by fundamental deficiencies in available methods for 17 measuring autophagic activity, or flux. To overcome these limitations, we introduced the 18 photoconvertible protein Dendra2 into the MAP1LC3B locus of human cells via 19 CRISPR/Cas9 genome editing, enabling accurate and sensitive assessments of 20 autophagy in living cells by optical pulse labeling. High-content screening of 1,500 tool 21 compounds provided construct validity for the assay and uncovered many new 22 autophagy modulators. In an expanded screen of 24,000 diverse compounds, we 23 identified additional hits with profound effects on autophagy. Further, the autophagy 24 activator NVP-BEZ235 exhibited significant neuroprotective properties in a 25 neurodegenerative disease model. These studies confirm the utility of the Dendra2-LC3 26 assay, while simultaneously highlighting new autophagy-modulating compounds that 27 display promising therapeutic effects.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • ICCB-L Plate (10 Mm / 3.33 Mm) ICCB-L Well Vendor ID Chemical Name
    ICCB-L Plate ICCB-L Therapeutic Absorption Protein FDA Additional info Additional info Vendor_ID Chemical_Name CAS number Therapeutic class Target type Target names (10 mM / 3.33 mM) Well effect tissue binding approved type detail Pharmacological 3712 / 3716 A03 Prestw-1 Azaguanine-8 134-58-7 Oncology Antineoplastic tool 3712 / 3716 A05 Prestw-2 Allantoin 97-59-6 Dermatology Antipsoriatic Carbonic 3712 / 3716 A07 Prestw-3 Acetazolamide 59-66-5 Metabolism Anticonvulsant Enzyme Carbonic anhydrase GI tract Yes anhydrase Potential Plasmatic New therapeutic 3712 / 3716 A09 Prestw-4 Metformin hydrochloride 1115-70-4 Endocrinology Anorectic GI tract Yes anticancer proteins use agent Chemical Plasmatic classification Quaternary 3712 / 3716 A11 Prestw-5 Atracurium besylate 64228-81-5 Neuromuscular Curarizing Yes proteins (according ATC ammonium code) 3712 / 3716 A13 Prestw-6 Isoflupredone acetate 338-98-7 Endocrinology Anti-inflammatory Therapeutic Amiloride-sensitive classification Potassium- 3712 / 3716 A15 Prestw-7 Amiloride hydrochloride dihydrate 17440-83-4 Metabolism Antihypertensive LGIC GI tract Yes sodium channel, ENaC (according ATC sparing agent code) 3712 / 3716 A17 Prestw-8 Amprolium hydrochloride 137-88-2 Infectiology Anticoccidial Veterinary use Poultry Therapeutic Solute carrier family 12 Plasmatic classification Low-ceiling 3712 / 3716 A19 Prestw-9 Hydrochlorothiazide 58-93-5 Metabolism Antihypertensive Carrier GI tract Yes member 3 proteins (according ATC diuretic code) Chemical classification 3712 / 3716 A21 Prestw-10 Sulfaguanidine
    [Show full text]
  • National Licensed Medicine List of Afghanistan
    islamic republic of afghanistan ministry of public health general directorate of pharmaceutical affairs avicenna pharmaceutical institute National Licensed Medicine List of Afghanistan 2014 2 NATIONAL LICENSED MEDICINES LIST OF AFGHANISTAN Preface With thanks to God for enabling us, we present this revision of the national essential medicines list (EML) and the licensed medicines list (LML) of Afghanistan. These documents are critical to the delivery of quality health services across the country. The policy of the Ministry of Public Health (MoPH) of the Islamic Republic of Afghanistan includes ensuring that the population of Afghanistan has access to safe, effective, and affordable medicines to treat its primary health problems. The EML includes the medicines needed for adequately addressing the priority health problems defined in the MoPH’s health strategy. The LML includes the medicines listed in the EML and additional medicines for conditions not included as priorities in the present strategy and medicines used in private sector. The MoPH developed and published the national EML of Afghanistan for the first time in 1995 and the LML in 2003; the last revision and publication occurred in 2007. The EML and LML should be revised regularly in response to the rapid expansion of basic health services in Afghanistan since 2003, the changing of internationally and nationally recommended treatment protocols for some diseases, the presence of new and emergent diseases, and the withdrawal of some toxic medicines from treatment guidelines. To revise the EML and LML, the MoPH authorized the National Medicine Selection Committee (NMSC) to develop a detailed procedure for inclusion or exclusion of medicines from the 2007 lists.
    [Show full text]
  • Klasifikacija ATC 2019
    ATC 2019 ATCCode ATCDescription ATCDescriptionSI A ALIMENTARY TRACT AND METABOLISM ZDRAVILA ZA BOLEZNI PREBAVIL IN PRESNOVE A01 STOMATOLOGICAL PREPARATIONS ZDRAVILA V ZOBOZDRAVSTVU A01A Stomatological preparations Zdravila v zobozdravstvu A01AA Caries prophylactic agents Zdravila za zaščito pred zobnim kariesom A01AA01 sodium fluoride natrijev fluorid A01AA02 sodium monofluorophosphate natrijev monofluorofosfat A01AA03 olaflur olaflur A01AA04 stannous fluoride kositrov(II) fluorid A01AA30 combinations kombinacije A01AA51 sodium fluoride, combinations natrijev fluorid, kombinacije A01AB Antiinfectives and antiseptics for local oral treatment Protimikrobne učinkovine in antiseptiki za lokalno oralno zdravljenje A01AB02 hydrogen peroxide vodikov peroksid A01AB03 chlorhexidine klorheksidin A01AB04 amphotericin B amfotericin B A01AB05 polynoxylin polinoksilin A01AB06 domiphen domifen A01AB07 oxyquinoline oksikinolin A01AB08 neomycin neomicin A01AB09 miconazole mikonazol A01AB10 natamycin natamicin A01AB11 various razne učinkovine A01AB12 hexetidine heksetidin A01AB13 tetracycline tetraciklin A01AB14 benzoxonium chloride benzoksonijev klorid A01AB15 tibezonium iodide tibezonijev jodid A01AB16 mepartricin mepartricin A01AB17 metronidazole metronidazol A01AB18 clotrimazole klotrimazol A01AB19 sodium perborate natrijev perborat A01AB21 chlortetracycline klortetraciklin A01AB22 doxycycline doksiciklin A01AB23 minocycline minociklin A01AC Corticosteroids for local oral treatment Kortikosteroidi za lokalno oralno zdravljenje A01AC01 triamcinolone
    [Show full text]